Member Info for Abouttime

AI Overview

+2

Yes, STX, which refers to Shield Therapeutics, is aiming to become cash flow positive by the end of 2025. They are on track to achieve this goal, as reported in recent updates. The company has seen strong growth in revenues and prescriptions for their product ACCRUFeR®, and they have also taken steps to strengthen their balance sheet.

Here's a more detailed breakdown:

Target:

Shield Therapeutics has publicly stated their goal of becoming cash flow positive by the end of 2025.

Progress:

They have reported positive momentum in their commercial performance, particularly with ACCRUFeR®, and have seen significant revenue growth.

Financials:

They have secured additional funding to support their objective and have taken steps to improve their balance sheet.

Key Metrics:

In Q1 2025, ACCRUFeR® net revenue was $6.4 million, and March represented nearly 50% of total Q1 net product revenues.

Full Year 2024:

Total revenues for FY24 were $32.2 million, with ACCRUFeR® revenues growing 153% to $29.3 million.

Just remember that STX have started shipping to Japan. This is a start of something big.

Two Foreign Trades. £1100 and £250

There was a director buy in February for 3.70. But we need more internal buys. Plus news soon. NEWS SOON.

Buys coming in at 1.10. Hopefully it will hold. And the short sellers can do one. Might see 1.25 by Friday

We need some directors buys. And some news. I've been here a while. believe this will go to 16p. May be 2027. Once Financial break even this year. 4p by December.

Still here, watching closely. Just interested what others are on. I'm obviously on Mast, and met1, stx.

90 to buy, we're off to the races again

93 to buy. Still cheap

Cheap as chips, ps chips have shot up.lol

Https://m.youtube.com/watch?v=RhFXlLsM2cM&list=PLnk_WM-WosgXc0Z7jHkSXbAhvXFrmqGZ3&pp=iAQB

According to the 3 industry analysts covering Shield Therapeutics, the consensus is that breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$32m in 2027. So, the company is predicted to breakeven approximately 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 89% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

On Friday there was alot of de ramping. Trying to get the stock back down to buy in low. Hopefully they have gone.

My opinion is this will see a rise to 1.15 today. End of week 1.22 to 1.27

Buys coming in today. Roll on Monday

Getting closer.

1.14

Where is the Volume? This should be 4p right now.

Nice to see this rising again. News soon.

Buys showing as sells....

Should be 890 today